Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $122.64

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned a consensus rating of “Moderate Buy” from the twenty-three analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $124.4783.

A number of equities analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Kymera Therapeutics in a research note on Thursday. They issued a “hold” rating and a $120.00 price target on the stock. Morgan Stanley restated an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Royal Bank Of Canada downgraded Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and raised their price target for the stock from $106.00 to $115.00 in a research note on Monday, July 13th. Finally, Canaccord Genuity Group lifted their price target on Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a report on Friday, June 26th.

Insider Buying and Selling at Kymera Therapeutics

In other news, Director Bruce Booth sold 467,878 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the transaction, the director owned 472,267 shares of the company’s stock, valued at approximately $52,086,327.43. This represents a 49.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 80,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total value of $9,223,200.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at $76,848,624.72. The trade was a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,607,813 shares of company stock worth $387,818,004 in the last ninety days. Insiders own 15.98% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after acquiring an additional 98 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the last quarter. Larson Financial Group LLC boosted its stake in Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics during the 4th quarter valued at approximately $63,000. Finally, Osaic Holdings Inc. grew its holdings in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the last quarter.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $103.40 on Monday. The stock has a market cap of $8.51 billion, a PE ratio of -28.96 and a beta of 1.95. Kymera Therapeutics has a fifty-two week low of $36.65 and a fifty-two week high of $130.05. The stock’s 50-day moving average is $98.92 and its two-hundred day moving average is $87.67.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm’s revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.82) earnings per share. On average, equities research analysts anticipate that Kymera Therapeutics will post -3.28 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.